{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T12:48:12Z","timestamp":1769431692646,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s00520-022-07265-2","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T07:02:46Z","timestamp":1657090966000},"page":"8151-8158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the safety and effectiveness of PegaGen\u00ae (pegfilgrastim) for the prevention of chemotherapy-induced febrile neutropenia: a post-marketing surveillance study"],"prefix":"10.1007","volume":"30","author":[{"given":"Arash","family":"Jenabian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Ehsanpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Mohammad Reza","family":"Mortazavizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jahangir","family":"Raafat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Khosravi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharareh","family":"Seifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babak","family":"Salimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nassim","family":"Anjidani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamidreza","family":"Kafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"issue":"9","key":"7265_CR1","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1002\/cncr.20983","volume":"103","author":"V Caggiano","year":"2005","unstructured":"Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT (2005) Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103(9):1916\u20131924","journal-title":"Cancer"},{"issue":"23","key":"7265_CR2","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1002\/cncr.25332","volume":"116","author":"GH Lyman","year":"2010","unstructured":"Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J (2010) Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 116(23):5555\u201363","journal-title":"Cancer"},{"issue":"4","key":"7265_CR3","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):e56\u2013e93","journal-title":"Clin Infect Dis"},{"issue":"28","key":"7265_CR4","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33(28):3199\u20133212","journal-title":"J Clin Oncol"},{"issue":"suppl_5","key":"7265_CR5","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, De Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M et al (2016) Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol 27(suppl_5):v111\u2013v8","journal-title":"Ann Oncol"},{"issue":"8","key":"7265_CR6","doi-asserted-by":"publisher","first-page":"979","DOI":"10.6004\/jnccn.2015.0118","volume":"13","author":"D Weycker","year":"2015","unstructured":"Weycker D, Li X, Barron R, Wu H, Morrow P, Xu H et al (2015) Importance of risk factors for febrile neutropenia among patients receiving chemotherapy regimens not classified as high-risk in guidelines for myeloid growth factor use. J Natl Compr Canc Netw 13(8):979\u2013986","journal-title":"J Natl Compr Canc Netw"},{"issue":"31","key":"7265_CR7","doi-asserted-by":"publisher","first-page":"7974","DOI":"10.1200\/JCO.2004.00.7955","volume":"23","author":"JN Timmer-Bonte","year":"2005","unstructured":"Timmer-Bonte JN, de Boo TM, Smit HJ, Biesma B, Wilschut FA, Cheragwandi SA et al (2005) Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 23(31):7974\u20137984","journal-title":"J Clin Oncol"},{"issue":"6","key":"7265_CR8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","volume":"10","author":"GH Lyman","year":"2005","unstructured":"Lyman GH, Lyman CH, Agboola O, oncologist ASGJT (2005) Risk models for predicting chemotherapy-induced neutropenia Oncologist. Oncologist 10(6):427\u2013437","journal-title":"Oncologist"},{"issue":"21","key":"7265_CR9","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1200\/JCO.2004.03.213","volume":"22","author":"GH Lyman","year":"2004","unstructured":"Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RIJJOCO (2004) Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin\u2019s lymphoma: a nationwide study. J Clin Oncol 22(21):4302\u20134311","journal-title":"J Clin Oncol"},{"issue":"9","key":"7265_CR10","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00520-006-0034-9","volume":"14","author":"M Schwenkglenks","year":"2006","unstructured":"Schwenkglenks M, Jackisch C, Constenla M, Kerger JN, Paridaens R, Auerbach L et al (2006) Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Support Care Cancer 14(9):901\u2013909","journal-title":"Support Care Cancer"},{"issue":"2","key":"7265_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1200\/JCO.2000.18.2.325","volume":"18","author":"E Voog","year":"2000","unstructured":"Voog E, Bienvenu J, Warzocha K, Moullet I, Dumontet C, Thieblemont C et al (2000) Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system. J Clin Oncol 18(2):325\u201331","journal-title":"J Clin Oncol"},{"issue":"3\u20134","key":"7265_CR12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3109\/10428190009089435","volume":"37","author":"T Intragumtornchai","year":"2000","unstructured":"Intragumtornchai T, Sutheesophon J, Sutcharitchan P, Swasdikul DJL (2000) A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin\u2019s lymphoma. Leuk Lymphoma 37(3\u20134):351\u2013360. https:\/\/doi.org\/10.3109\/10428190009089435","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"7265_CR13","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","volume":"18","author":"J Klastersky","year":"2000","unstructured":"Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R et al (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038\u20133051","journal-title":"J Clin Oncol"},{"issue":"11","key":"7265_CR14","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1200\/JCO.1995.13.11.2688","volume":"13","author":"L Gianni","year":"1995","unstructured":"Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F et al (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13(11):2688\u201399","journal-title":"J Clin Oncol"},{"issue":"4","key":"7265_CR15","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.ejca.2008.11.021","volume":"45","author":"G Von Minckwitz","year":"2009","unstructured":"Von Minckwitz G, Schwenkglenks M, Skacel T, Lyman G, Pousa AL, Bacon P et al (2009) Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. Eur J Cancer 45(4):608\u2013617","journal-title":"Eur J Cancer"},{"issue":"15","key":"7265_CR16","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","volume":"42","author":"MS Aapro","year":"2006","unstructured":"Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M et al (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42(15):2433\u20132453","journal-title":"Eur J Cancer"},{"issue":"11","key":"7265_CR17","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00520-008-0430-4","volume":"16","author":"R Pettengell","year":"2008","unstructured":"Pettengell R, Schwenkglenks M, Leonard R, Bosly A, Paridaens R, Constenla M et al (2008) Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 16(11):1299\u20131309","journal-title":"Support Care Cancer"},{"issue":"8","key":"7265_CR18","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.2009.24.8872","volume":"28","author":"SLHJLMBB SpuntIrvingFrostSenderGuoYang","year":"2010","unstructured":"SpuntIrvingFrostSenderGuoYang SLHJLMBB et al (2010) Phase II, randomized, open-label study of pegfilgrastim-supported VDC\/IE chemotherapy in pediatric sarcoma patients. J Clin Oncol 28(8):1329","journal-title":"J Clin Oncol"},{"key":"7265_CR19","unstructured":"DeVita VT, Lawrence TS, Rosenberg SA (2018) DeVita, Hellman, and Rosenberg\u2019s cancer: principles & practice of oncology. Philadelphia"},{"issue":"1","key":"7265_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/annonc\/mdg019","volume":"14","author":"M Green","year":"2003","unstructured":"Green M, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14(1):29\u201335","journal-title":"Ann Oncol"},{"issue":"3","key":"7265_CR21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","volume":"20","author":"F Holmes","year":"2002","unstructured":"Holmes F, O\u2019Shaughnessy J, Vukelja S, Jones S, Shogan J, Savin M et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer. J Clin Oncol 20(3):727\u201331","journal-title":"J Clin Oncol"},{"issue":"23","key":"7265_CR22","doi-asserted-by":"publisher","first-page":"7361","DOI":"10.1158\/1078-0432.CCR-09-0761","volume":"15","author":"E Fox","year":"2009","unstructured":"Fox E, Widemann BC, Hawkins DS, Jayaprakash N, Dagher R, Aikin AA et al (2009) Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. Clin Cancer Res 15(23):7361\u20137367","journal-title":"Clin Cancer Res"},{"issue":"6","key":"7265_CR23","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/CAD.0b013e3283610b5d","volume":"24","author":"Y-K Shi","year":"2013","unstructured":"Shi Y-K, Chen Q, Zhu Y-Z, He X-H, Wang H-Q, Jiang Z-F et al (2013) Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study. Anticancer Drugs 24(6):641\u20137","journal-title":"Anticancer Drugs"},{"issue":"2","key":"7265_CR24","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00520-014-2457-z","volume":"23","author":"AMKRGMS von PfeilAllcottPettengellMinckwitzSchw","year":"2015","unstructured":"von PfeilAllcottPettengellMinckwitzSchwenkglenksZJScic AMKRGMS (2015) Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Support Care Cancer 23(2):525\u2013545","journal-title":"Support Care Cancer"},{"issue":"1","key":"7265_CR25","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1471-2407-11-404","volume":"11","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11(1):404","journal-title":"BMC Cancer"},{"issue":"1","key":"7265_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-37186-2","volume":"9","author":"Y Wang","year":"2019","unstructured":"Wang Y, Chen L, Liu F, Zhao N, Xu L, Fu B et al (2019) Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: a systematic review and Bayesian network meta-analysis. Sci Rep 9(1):1\u201312","journal-title":"Sci Rep"},{"issue":"2","key":"7265_CR27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4103\/2229-3485.71852","volume":"1","author":"VJPICR Suvarna","year":"2010","unstructured":"Suvarna VJPICR (2010) Phase IV of drug development. Perspect Clin Res 1(2):57","journal-title":"Perspect Clin Res"},{"issue":"2","key":"7265_CR28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.31887\/DCNS.2011.13.2\/hmoeller","volume":"13","author":"H-JJDICN M\u00f6ller","year":"2011","unstructured":"M\u00f6ller H-JJDICN (2011) Effectiveness studies: advantages and disadvantages. Dialogues Clin Neurosci 13(2):199","journal-title":"Dialogues Clin Neurosci"},{"key":"7265_CR29","unstructured":"http:\/\/eudragmdp.ema.europa.eu\/inspections\/gmpc\/searchGMPCompliance.do. Available from: http:\/\/eudragmdp.ema.europa.eu\/inspections\/gmpc\/searchGMPCompliance.do.\u00a0Accessed 4 April 2021"},{"key":"7265_CR30","unstructured":"SUMMARY OF PRODUCT CHARACTERISTICS, Neulasta, INN-pegfilgrastim - European Medicines Agency\u00a0Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/neulasta-epar-product-information_en.pdf.\u00a0Accessed 4 April 2021"},{"issue":"12","key":"7265_CR31","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1634\/theoncologist.12-12-1416","volume":"12","author":"L Balducci","year":"2007","unstructured":"Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L et al (2007) Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 12(12):1416\u20131424","journal-title":"Oncologist"},{"issue":"2","key":"7265_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clcc.2016.08.008","volume":"16","author":"T Pinter","year":"2017","unstructured":"Pinter T, Klippel Z, Cesas A, Croitoru A, Decaestecker J, Gibbs P et al (2017) A phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients receiving first-line FOLFOX\/bevacizumab or FOLFIRI\/bevacizumab for locally advanced or metastatic colorectal cancer: final results of the pegfilgrastim and anti-VEGF evaluation study (PAVES). Clin Colorectal Cancer 16(2):103\u2013143","journal-title":"Clin Colorectal Cancer"},{"issue":"6","key":"7265_CR33","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23(6):1178\u20131184","journal-title":"J Clin Oncol"},{"issue":"3","key":"7265_CR34","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1200\/JCO.2003.03.040","volume":"21","author":"JM Vose","year":"2003","unstructured":"Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J et al (2003) Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 21(3):514\u2013519","journal-title":"J Clin Oncol"},{"issue":"5","key":"7265_CR35","doi-asserted-by":"publisher","first-page":"223","DOI":"10.4174\/astr.2018.94.5.223","volume":"94","author":"J Lee","year":"2018","unstructured":"Lee J, Lee JE, Kim Z, Han SW, Hur SM, Kim SY et al (2018) Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy. Ann Surg Treatment Res 94(5):223\u2013228","journal-title":"Ann Surg Treatment Res"},{"issue":"1","key":"7265_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4103\/2278-330X.202560","volume":"6","author":"V Talwar","year":"2017","unstructured":"Talwar V, Nirni SS, Mallavarapu KM, Ramkumar A, Sinha N (2017) Safety and tolerability of Peg-grafeel\u2122, a pegfilgrastim, for the prophylactic treatment of chemotherapy-induced neutropenia and febrile neutropenia: a prospective, observational, postmarketing surveillance study in India. South Asian J Cancer 6(1):20","journal-title":"South Asian J Cancer"},{"issue":"4","key":"7265_CR37","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00520-014-2597-1","volume":"23","author":"Y Kosaka","year":"2015","unstructured":"Kosaka Y, Rai Y, Masuda N, Takano T, Saeki T, Nakamura S et al (2015) Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel\/cyclophosphamide chemotherapy. Support Care Cancer 23(4):1137\u20131143","journal-title":"Support Care Cancer"},{"issue":"3","key":"7265_CR38","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/ecc.12043","volume":"22","author":"D Almenar Cubells","year":"2013","unstructured":"Almenar Cubells D, Bosch Roig C, Jimenez Orozco E, Alvarez R, Cuervo J, Diaz Fernandez N et al (2013) Effectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice. Eur J Cancer Care 22(3):400\u2013412","journal-title":"Eur J Cancer Care"},{"issue":"9","key":"7265_CR39","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1177\/1060028017706373","volume":"51","author":"DC Moore","year":"2017","unstructured":"Moore DC, Pellegrino AE (2017) Pegfilgrastim-induced bone pain: a review on incidence, risk factors, and evidence-based management. Ann Pharmacother 51(9):797\u2013803","journal-title":"Ann Pharmacother"},{"issue":"2","key":"7265_CR40","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/annonc\/mdm438","volume":"19","author":"G Von Minckwitz","year":"2008","unstructured":"Von Minckwitz G, K\u00fcmmel S, Du Bois A, Eiermann W, Eidtmann H, Gerber B et al (2008) Pegfilgrastim\u00b1ciprofloxacin for primary prophylaxis with TAC (docetaxel\/doxorubicin\/cyclophosphamide) chemotherapy for breast cancer Results from the GEPARTRIO study. Ann Oncol 19(2):292\u20138","journal-title":"Ann Oncol"},{"issue":"4","key":"7265_CR41","doi-asserted-by":"publisher","first-page":"337","DOI":"10.18553\/jmcp.2007.13.4.337","volume":"13","author":"VA Morrison","year":"2007","unstructured":"Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J (2007) Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3\u20134 week chemotherapy regimens in community oncology practices. J Manag Care Pharm 13(4):337\u2013348","journal-title":"J Manag Care Pharm"},{"issue":"4","key":"7265_CR42","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1159\/000094890","volume":"70","author":"W Schippinger","year":"2006","unstructured":"Schippinger W, Holub R, Dandachi N, Bauernhofer T, Samonigg H (2006) Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel\/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim. Oncology 70(4):290\u2013293","journal-title":"Oncology"},{"key":"#cr-split#-7265_CR43.1","doi-asserted-by":"crossref","unstructured":"Brito M, Esteves S, Andre R, Isidoro M, Moreira A (2012) Abstract P1-15-03: Comparison of efficacy of primary prophylaxis with pegfilgrastim, filgrastrim and a biosimilar filgrastim in TAC regimen (docetaxel, doxorubicin and cyclophosphamide). In: Poster Session Abstracts [Internet]. American Association for Cancer Research","DOI":"10.1158\/0008-5472.SABCS12-P1-15-03"},{"key":"#cr-split#-7265_CR43.2","unstructured":"2012 [cited 2021 Jan 3]. p. P1-15-03-P1-15-03. Available from: http:\/\/cancerres.aacrjournals.org\/lookup\/doi\/10.1158\/0008-5472.SABCS12-P1-15-03"},{"issue":"5","key":"7265_CR44","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1185\/03007995.2013.781018","volume":"29","author":"M Fiegl","year":"2013","unstructured":"Fiegl M, Steger GG, Studnicka M, Eisterer W, Jaeger C, Willenbacher W (2013) Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational study. Curr Med Res Opin 29(5):505\u2013515","journal-title":"Curr Med Res Opin"},{"key":"7265_CR45","doi-asserted-by":"crossref","unstructured":"Ozer H, Mirtsching B, Rader M, Luedke S, Noga SJ, Ding B, et al (2007) Neutropenic events in community practices reduced by First and subsequent cycle pegfilgrastim use. Oncologist 12(4):484\u201394","DOI":"10.1634\/theoncologist.12-4-484"},{"issue":"28","key":"7265_CR46","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33(28):3199\u20133212","journal-title":"J Clin Oncol"},{"issue":"4","key":"7265_CR47","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/s00520-018-4473-x","volume":"27","author":"JP Salmon","year":"2019","unstructured":"Salmon JP, Smakal M, Karanikiotis C, Wojtukiewicz MZ, Omnes Y, DeCosta L et al (2019) Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin\u2019s lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study. Support Care Cancer 27(4):1449\u20131457","journal-title":"Support Care Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07265-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07265-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07265-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T15:30:20Z","timestamp":1727537420000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07265-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["7265"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07265-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,6]]},"assertion":[{"value":"11 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from the Institutional Research Ethics Committee of Islamic Azad Tehran Medical Sciences University (#IR.IAU.PS.REC.1399.067) and was carried out according to the principles of the Declaration of Helsinki. All participants signed the written informed consent prior to starting the study. The trial was registered at ClinicalTrials.gov (#NCT04460079).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Consent form is applicable for this study in the Persian language and uploaded as a supplementary file. Also, it can be translated and uploaded in English language later as it is needed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NA is the head of the medical department of Orchid Pharmed Company, which is in collaboration with CinnaGen Company with respect to conducting clinical trials. HA is head of advisory board in Orchid Pharmed Company. No other potential conflicts of interest relevant to this article were reported.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}